Abstract

Coronary artery disease (CAD), with its variable presentations, was the commonest cause of death (13.3%) in 2010, increasing by 26–35% from 1990 to 2010 (1).
Acute coronary syndrome (ACS), an acute presentation of CAD, always carries the highest risk of adverse cardiovascular events. Good management, based on early risk stratification, can lead to better outcomes. Scoring systems, including the Global Registry of Acute Coronary Events (GRACE) (2), and thrombolysis in myocardial infarction (TIMI) (3), were developed to identify patients with the highest risk for worse outcomes and to treat them early and successfully.
Coronary artery anatomy can be detected using coronary angiography (CAG), and CAD severity can be evaluated using the SYNTAX and Gensini scores (4).
The CHA2DS2-VASc score is utilized to predict the risk of embolic stroke in non-valvular atrial fibrillation (AF) (5). It has likewise been utilized as a tool to predict reperfusion failure in myocardial infarction (MI) and risk of stroke during ACS (4).
Because the CHA2DS2-VASc scoring scheme is easily remembered and can be applied by physicians at the bedside, its ability to predict CAD severity was investigated by Cetin et al., in stable CAD patients (6) and by Chua et al, in the ACS setting (7).
In the present study, we aimed to validate the CHA2DS2-VASc score within the ACS setting in terms of CAD severity as well as short-term and long-term clinical events